CD274 and breast carcinoma: Conceivably, for PD-L1-low breast cancers, combination activity may be greater than what is predicted by the EMT-6/CDDP model, with PTX being a more promising partner than sunitinib or B20 for combining with adjuvant anti-PD-L1 therapy.